← Lumefantrine

Patient counseling sheet

Print-ready and generated without storing patient details.

AfyaIndex · counseling handout

Lumefantrine

Antimalarial

Prepared 19 Sep 2026

What it is used for

Therapeutic use is agent- and indication-specific within the class (Antimalarial). Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC. Clinical selection for Lumefantrine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Antimalarial. Confirm site-specific dose, duration and monitoring before prescribing.

Warnings

Confirm species and severity. ECG risk with some agents (quinine, piperaquine). Pregnancy: follow Kenya/WHO trimester-specific ACT guidance. Vomiting within 30–60 min may need redosing per protocol.

Possible side effects

GI upset, headache, dizziness, sleep disturbance (mefloquine). Serious: cardiotoxicity, neuropsychiatric effects, haemolysis (primaquine in G6PD def.), cinchonism (quinine).

Storage

Store as labelled. Keep out of reach of children.

No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.

AfyaIndex dataset coverage